Total Payments
$35,036
2024 Payments
$10,744
Companies
44
Transactions
1,114
Medicare Patients
4,256
Medicare Billing
$443,572
Payment Breakdown by Category
Other$19,125 (54.6%)
Food & Beverage$15,040 (42.9%)
Gifts$569.88 (1.6%)
Consulting$150.00 (0.4%)
Travel$93.80 (0.3%)
Education$56.59 (0.2%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $19,125 | 11 | 54.6% |
| Food and Beverage | $15,040 | 1,084 | 42.9% |
| Gift | $569.88 | 8 | 1.6% |
| Consulting Fee | $150.00 | 1 | 0.4% |
| Travel and Lodging | $93.80 | 2 | 0.3% |
| Education | $56.59 | 8 | 0.2% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| ABBVIE INC. | $23,744 | 282 | $0 (2024) |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | $3,516 | 359 | $0 (2024) |
| Braintree Laboratories, Inc. | $1,068 | 43 | $0 (2024) |
| Allergan, Inc. | $689.61 | 83 | $0 (2020) |
| IRONWOOD PHARMACEUTICALS, INC | $685.87 | 43 | $0 (2024) |
| PFIZER INC. | $611.43 | 43 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $594.76 | 43 | $0 (2024) |
| GENZYME CORPORATION | $374.20 | 18 | $0 (2024) |
| Celgene Corporation | $355.62 | 31 | $0 (2024) |
| Synergy Pharmaceuticals Inc | $308.67 | 24 | $0 (2018) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $10,744 | 133 | ABBVIE INC. ($9,563) |
| 2023 | $10,759 | 175 | AbbVie Inc. ($9,177) |
| 2022 | $4,388 | 138 | ABBVIE INC. ($3,108) |
| 2021 | $2,015 | 147 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($633.06) |
| 2020 | $1,611 | 124 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($542.62) |
| 2019 | $2,001 | 156 | Salix Pharmaceuticals, a division of Bausch Health US, LLC ($693.75) |
| 2018 | $2,200 | 144 | AbbVie, Inc. ($350.96) |
| 2017 | $1,318 | 97 | AbbVie, Inc. ($379.38) |
All Payment Transactions
1,114 individual payment records from CMS Open Payments — Page 1 of 45
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $4.84 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | IRONWOOD PHARMACEUTICALS, INC | Linzess (Drug) | Food and Beverage | Cash or cash equivalent | $19.65 | General |
| Category: GI | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | TRULANCE (Drug) | Food and Beverage | In-kind items and services | $14.00 | General |
| Category: Gastroenterology | ||||||
| 12/18/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $12.03 | General |
| Category: Gastroenterology | ||||||
| 12/17/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $22.82 | General |
| Category: GASTROENTEROLOGY | ||||||
| 12/12/2024 | ABBVIE INC. | SKYRIZI (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,425.00 | General |
| Category: IMMUNOLOGY | ||||||
| 12/11/2024 | Takeda Pharmaceuticals U.S.A., Inc. | EOHILIA (Drug) | Food and Beverage | In-kind items and services | $22.00 | General |
| Category: INTERNAL MEDICINE | ||||||
| 12/11/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $17.25 | General |
| Category: LIVER DISEASE | ||||||
| 12/11/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $5.96 | General |
| Category: Gastroenterology | ||||||
| 12/10/2024 | ABBVIE INC. | CREON (Drug), LINZESS | Food and Beverage | In-kind items and services | $12.44 | General |
| Category: ENDOCRINOLOGY | ||||||
| 12/06/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $19.50 | General |
| Category: Immunology | ||||||
| 12/03/2024 | ABBVIE INC. | RINVOQ (Biological), SKYRIZI | Food and Beverage | In-kind items and services | $8.21 | General |
| Category: IMMUNOLOGY | ||||||
| 12/03/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $6.68 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/27/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $15.74 | General |
| Category: Gastroenterology | ||||||
| 11/27/2024 | ABBVIE INC. | MAVYRET (Drug) | Food and Beverage | In-kind items and services | $14.81 | General |
| Category: VIROLOGY | ||||||
| 11/20/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $22.79 | General |
| Category: Immunology | ||||||
| 11/20/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $6.75 | General |
| Category: Gastroenterology | ||||||
| 11/19/2024 | ABBVIE INC. | VIBERZI (Drug), CREON | Food and Beverage | In-kind items and services | $19.47 | General |
| Category: GASTROENTEROLOGY | ||||||
| 11/13/2024 | GENZYME CORPORATION | DUPIXENT (Biological) | Food and Beverage | In-kind items and services | $14.57 | General |
| Category: Immunology | ||||||
| 11/12/2024 | ABBVIE INC. | LINZESS (Drug), VIBERZI, CREON | Food and Beverage | In-kind items and services | $19.30 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/30/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $15.67 | General |
| Category: GASTROENTEROLOGY | ||||||
| 10/29/2024 | Janssen Biotech, Inc. | TREMFYA (Drug) | Food and Beverage | In-kind items and services | $17.19 | General |
| Category: Immunology | ||||||
| 10/23/2024 | Salix Pharmaceuticals, a division of Bausch Health US, LLC | XIFAXAN (Drug) | Food and Beverage | In-kind items and services | $16.15 | General |
| Category: Gastroenterology | ||||||
| 10/23/2024 | Madrigal Pharmaceuticals | RESMETIROM (Drug) | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: LIVER DISEASE | ||||||
| 10/22/2024 | Phathom Pharmaceuticals, Inc. | VOQUEZNA (Drug) | Food and Beverage | In-kind items and services | $15.73 | General |
| Category: GASTROENTEROLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 14 | 1,006 | 1,171 | $608,756 | $108,682 |
| 2022 | 14 | 1,016 | 1,144 | $619,322 | $111,640 |
| 2021 | 15 | 1,105 | 1,285 | $607,404 | $116,204 |
| 2020 | 13 | 1,129 | 1,383 | $521,997 | $107,046 |
Total Patients
4,256
Total Services
4,983
Medicare Billing
$443,572
Procedure Codes
56
All Medicare Procedures & Services
56 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2023 | 206 | 206 | $276,452 | $36,715 | 13.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 194 | 259 | $44,030 | $14,169 | 32.2% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 178 | 184 | $76,544 | $12,601 | 16.5% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 87 | 103 | $23,175 | $9,735 | 42.0% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2023 | 42 | 42 | $23,730 | $7,008 | 29.5% |
| 99231 | Subsequent hospital care with straightforward or low level of medical decision making, per day, if using time, at least 25 minutes | Facility | 2023 | 54 | 127 | $15,240 | $4,538 | 29.8% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2023 | 24 | 24 | $13,560 | $4,014 | 29.6% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2023 | 33 | 33 | $17,721 | $3,679 | 20.8% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2023 | 26 | 27 | $22,518 | $3,276 | 14.5% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2023 | 44 | 44 | $8,580 | $2,992 | 34.9% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2023 | 40 | 40 | $39,600 | $2,956 | 7.5% |
| 43235 | Diagnostic exam of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2023 | 38 | 38 | $29,792 | $2,773 | 9.3% |
| 43249 | Balloon dilation of esophagus, stomach, and/or upper small bowel using a flexible endoscope, less than 3.0 cm | Facility | 2023 | 24 | 26 | $13,494 | $2,598 | 19.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 16 | 18 | $4,320 | $1,629 | 37.7% |
| 45385 | Removal of polyps or growths of large bowel using an endoscope with mechanical snare | Facility | 2022 | 202 | 204 | $273,768 | $36,539 | 13.3% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 195 | 253 | $43,010 | $14,314 | 33.3% |
| 43239 | Biopsy of esophagus, stomach, and/or upper small bowel using a flexible endoscope | Facility | 2022 | 182 | 191 | $79,456 | $13,174 | 16.6% |
| G0105 | Colorectal cancer screening; colonoscopy on individual at high risk | Facility | 2022 | 63 | 63 | $35,595 | $10,723 | 30.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 63 | 68 | $15,300 | $6,715 | 43.9% |
| 45378 | Diagnostic exam of large bowel using a flexible endoscope | Facility | 2022 | 36 | 37 | $30,858 | $4,820 | 15.6% |
| 45380 | Biopsy of large bowel using a flexible endoscope | Facility | 2022 | 44 | 44 | $43,560 | $4,238 | 9.7% |
| 99203 | New patient office or other outpatient visit, 30-44 minutes | Office | 2022 | 60 | 60 | $11,700 | $4,214 | 36.0% |
| 43248 | Insertion of guide wire with dilation of esophagus using a flexible endoscope | Facility | 2022 | 34 | 35 | $18,795 | $3,954 | 21.0% |
| G0121 | Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk | Facility | 2022 | 23 | 23 | $12,995 | $3,921 | 30.2% |
| 99231 | Follow-up hospital inpatient care per day, typically 15 minutes | Facility | 2022 | 45 | 92 | $11,040 | $2,613 | 23.7% |
About Dr. Mark Voellinger, M.D
Dr. Mark Voellinger, M.D is a Gastroenterology healthcare provider based in Wheeling, West Virginia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/07/2007. The National Provider Identifier (NPI) number assigned to this provider is 1619170693.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Mark Voellinger, M.D has received a total of $35,036 in payments from pharmaceutical and medical device companies, with $10,744 received in 2024. These payments were reported across 1,114 transactions from 44 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($19,125).
As a Medicare-enrolled provider, Voellinger has provided services to 4,256 Medicare beneficiaries, totaling 4,983 services with total Medicare billing of $443,572. Data is available for 4 years (2020–2023), covering 56 distinct procedure/service records.
Ad
Practice Information
- Specialty Gastroenterology
- Other Specialties Gastroenterology
- Location Wheeling, WV
- Active Since 06/07/2007
- Last Updated 02/26/2024
- Taxonomy Code 207RG0100X
- Entity Type Individual
- NPI Number 1619170693
Products in Payments
- SKYRIZI (Biological) $10,527
- RINVOQ (Biological) $9,815
- XIFAXAN (Drug) $2,245
- LINZESS (Drug) $1,203
- Linzess (Drug) $639.92
- SUTAB (Drug) $563.10
- VIBERZI (Drug) $560.18
- XELJANZ (Drug) $519.59
- CREON (Drug) $506.38
- TRULANCE (Drug) $475.68
- Humira (Biological) $436.07
- Creon (Drug) $431.53
- DUPIXENT (Biological) $399.14
- MAVYRET (Drug) $365.32
- HUMIRA (Biological) $359.93
- ZEPOSIA (Drug) $355.62
- RELISTOR (Drug) $341.42
- Trulance (Drug) $308.67
- APRISO (Drug) $279.26
- XIFAXANIBSD (Drug) $240.96
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.